scholarly journals The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective

2021 ◽  
Vol 8 ◽  
pp. 140-146
Author(s):  
Luis J. Pastor-Quirós ◽  
Edgar P. Correa-Díaz
Keyword(s):  
Multiple Sclerosis ◽  
New Technologies ◽  
Base Case ◽  
Baseline Scenario ◽  
Budgetary Impact ◽  
Escalation Therapy ◽  
Local Resources ◽  
Remitting Multiple Sclerosis ◽  
The Cost

Introduction: Multiple sclerosis is a neurological condition that causes disabilities and is most common in young adults. It imposes high financial costs affecting the quality of life of patients, families, and society. It is critical to measure the budgetary impact of new technologies to treat this disease. Objective: The aim of the article is to estimate the budgetary impact of introducing alemtuzumab as an escalation therapy in patients diagnosed with Recurrent Remitting Multiple Sclerosis and treated in Quito, Ecuador. Materials and methods: A cohort of 85 patients receiving treatment with disease-modifying therapies was used, within a 5-year timeframe, between 2021 and 2025. The baseline scenario, including the percentages of administration of the different drugs, is compared with the alternative scenario, including alemtuzumab. The cost assessment included only direct medical resources. To obtain local resources for management of the disease, a neurologist and clinical expert who treats most of the patients in Quito was consulted. Results: Considering a cohort of 85 patients with active Recurrent Remitting Multiple Sclerosis, the average global budget impact in 5 years would be USD 10,603,230.00 in the base case and USD 9,995,817.00 in the alemtuzumab scenario. Conclusion: The inclusion of alemtuzumab as escalation therapy represents budgetary savings over the next 5 years (2021-2025).

scholarly journals Current Issues in the Management of Genital Herpes

1995 ◽  
Vol 6 (6_suppl) ◽  
pp. 3-6 ◽  
Author(s):  
S. E. Barton
Keyword(s):  
General Practitioners ◽  
New Technologies ◽  
Clinical Manifestations ◽  
Best Interest ◽  
First Results ◽  
The Uk ◽  
Simplex Virus ◽  
The Cost ◽  
Antibody Tests

Genital infection by herpes simplex virus (HSV) produces a variety of clinical manifestations, patient presentations and management problems which differ in their severity and complexity. In the UK the currently available data for the incidence of genital HSV have been provided predominantly by the KC60 returns from diagnoses made in genitourinary (GU) medicine clinics. The increasing availability and recent publication of the first results, using HSV type-specific antibody tests within GU and non-GU patient populations, provide a tool to monitor trends in the epidemiology of HSV. It is, however, important to understand that the sexual behaviour which leads to this infection is variable and not necessarily general. The clinical availability of type-specific HSV antibody tests also gives rise to the possibility of screening individuals and informing those who test positive of their, previously undiagnosed, condition. The practicalities and problems of this approach need to be fully assessed. The possibility of uncovering previously undiagnosed cases through general practitioners is being considered, first, in terms of surveys of the general practitioners' management of genital HSV and, secondly, because the funding of health care in the UK has put the cost-effectiveness in GU medicine clinics under the spotlight. This paper will explore the new developments in the management of genital HSV and suggests adherence to the clear principles of diagnosis and treatment that is in the patient's best interest. This has the clear aim of improving the patient's quality of life, a factor which must remain paramount as new technologies, healthcare strategies and therapies become available.

Sign in / Sign up

Export Citation Format

Share Document